Big Phrama Greed Hard at Work in Ohio
The drug industry will say anything, do anything to defeat the Ohio Drug Price Relief Act (drug relief act) – or any other effort to control their drug prices. We are already seeing how this plays out.
The industry’s lobbying arm, the Pharmaceutical Research and Manufacturers of America (PhRMA), hired the Columbus law firm of Bricker & Eckler to use every legal trick in the book to prevent the drug relief act from getting on the ballot – even after nearly 200,000 Ohioans signed petitions to put it there. But PhRMA’s efforts to quash this citizen reform movement was defeated by an Ohio Supreme Court ruling.
PhRMA subsequently spent big bucks to hire Vorys Health Care Advisors LLC to write an analysis of the drug relief act. Not surprisingly, the drug industry got what it paid for – a thinly-disguised hit piece.
The Vorys report is built on unsupported assumptions, shaky speculation and even unnamed sources. Its conclusion is that Ohio government agencies won’t gain from passage of the drug relief act because the drug companies are already giving those agencies the same kind of discounts the drug relief act would mandate. Vorys based that conclusion on interviews with unnamed state officials. Oh yeah? Now if the drug relief act will have no impact on drug prices, why is the drug industry ready to spend tens of millions to defeat the measure? It makes no sense.
The Vorys report also claims Ohio cannot find out what the U.S. Dept. of Veterans Affairs pays for its drugs (the benchmark for what the Ohio agencies would pay under the drug relief act) because that payment information is cloaked in proprietary secrecy. It’s only the drug companies that want the exact prices kept secret. There should be no problem with the VA sharing with Ohio what it pays for its drugs. Ohio can keep a secret as well as the VA. So what’s the problem? This argument is more drug company smoke and mirrors.
Finally, Vorys claims that if the drug companies must lower drug prices because of the drug relief act the result would be that the drug companies would evade the measure’s impact by jacking up the prices they charge the VA. Now how’s that going to look? Drug companies sock it to veterans? This would give the companies such a black eye that they would be lucky if the entire consuming public, the Congress and the President didn’t go ballistic on them. In other words, this scenario is not likely unless the drug companies are suicidal.
Remember: the only one who can raise the price of drugs are the drug companies. So when they say the relief act will cause higher drug prices that’s a threat that only they make good on.
Bottom-line: the Vorys report is one bought and paid for by the drug companies It’s not credible. Fortunately Ohioans now have the option to vote yes in Nov. 2017 and get real relief from the drug companies’ painful price-gouging. And their malarkey.
Washington state’s top lawyer is suing Purdue Pharma, alleging it misled doctors and consumers about the addictive dangers of OxyContin, Purdue’s top-selling opioid, and also violated a 2007 federal court order requiring the controversial company to take action when...read more
When it discovered that too many Iraq and Afghanistan vets were taking too many opioids, the U.S. Dept. of Veterans Affairs launched a program to switch gears in 2012. Four years later the VA had 187,000 fewer patients on opioids. The number of vet-patients taking...read more
Congressman Elijah Cummings has turned to Twitter to urge Pres. Trump to use a patent the U.S. government holds to lower the price on a multiple sclerosis drug that is being sold by Biogen for $87,000. In his first tweet, Cummings wrote: “@realDonalTrump. Mr....read more
A federal district court judge recently refused to temporarily block implementation of Maryland’s new law against drug price gouging. The judge’s ruling was a setback for the drug industry. And it got worse. The judge also signaled that he doubted the industry could...read more
Because Washington, D.C. politicians can’t get their act together to curb drug prices, there has been a “noticeable uptick” in measures by state voter and legislatures to tackle this crisis, the Washington Post reports. The boldest of these efforts is Issue 2...read more
One day after Pres. Trump's harsh remarks about the drug companies' corrupt influence over the nation’s elected officials, the companies pumped a record amount of cash into the political coffers of many of these same officials. On March 20, 2017, in a speech in...read more
Medicare and Medicaid have been spending more to buy Harvoni, the $94,000 pill to cure hepatitis C made by Gilead Sciences, than the two giant health programs spent on any other drug. This has been the case even as a scathing U.S. Senate investigation found that...read more
Earlier this year, a half-dozen drug company CEOs, battered by bad publicity about outrageous drug price increases, pledged to cap their increases in 2017. But now that Pres. Trump is no longer badgering the industry about “getting away with murder” and news about...read more
Testifying before a U.S. Senate panel, the mother of a 32-year-old New Jersey woman who overdosed on an opioid prescription drug blamed “corporate greed” for her daughter’s death. Patricia Fuller, mother of Sarah Fuller, told the panel: “I believe that Sarah’s death...read more
It’s beginning to look like insulin may become the next EpiPen – in other words, a giant public relations headache. Last weekend, demonstrators with signs saying “your prices are killing us” gathered outside Eli Lilly’s corporate headquarters in Indianapolis to...read more